Using this SPON1 mAb, we demonstrated that the RFS in the SPON1-high group of ovarian cancer subjects is significantly lower than that in the SPON1-low group, and that high SPON1 expression is associated with various clinicopathological factors. This evidence concerns the gene SPON1 and ovarian carcinoma.